

APR 1 REC'D PCT/PTO 05 MAY 2006

RECEIVED  
CENTRAL FAX CENTER

MAY 05 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)  Total Number of Pages in This Submission	Application Number	10/539,936
	Filing Date	6/16/2005
	First Named Inventor	Gregory Basarab
	Art Unit	1614
	Examiner Name	Not yet known
	Attorney Docket Number	100909-1P US
8		

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> C.D. Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD  Remarks	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Combined Declaration and Power of Attorney Copy of USPTO office action

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AstraZeneca		
Signature			
Printed name	Heidi M. Berven		
Date	5 May 2006	Reg. No.	48,951

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Audrey Williams	Date	May 5, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

RECEIVED  
CENTRAL FAX CENTER

MAY 05 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/539,936	Applicant: Basarab <i>et al</i>
Filing Date: 6/16/2005	Attorney Docket No.: 100909-1P US
Examiner: Not yet known	Group Art Unit : 1614
Customer No.: 44992	Confirmation No.: 8394
Title: PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION	

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on May 5, 2006

  
Signature  
Audrey Williams


Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE MISSING REQUIREMENTS

Sir:

Responsive to the Notice to File Missing Requirements, dated 03/09/2006, applicant hereby encloses the executed Declaration and the required copy of the Notice to File Missing Parts. Applicant authorizes payment of the \$130 fee to be charged to deposit account number 50-3231.

Respectfully submitted,

  
Name: Heidi M. Berven  
Dated: May 5, 2006  
Reg. No.: 48,951  
Phone No.: 1 781 839 4336

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham, MA 02451

05/15/2006 GFREY1 00000148 503231 10539936  
01 FC:1617 130.00 DA

BEST AVAILABLE COPY

RECEIVED  
CENTRAL FAX CENTER

MAY 05 2006

MAY-23-2006 THU 02:59 PM astra zeneca r&amp;d boston

FAX NO. 17818394121

P. 02 0/0

Page 1 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/539,936	FIRST NAMED APPLICANT Gregory Basarab	ATTY. DOCKET NO. 100909-1P US
INTERNATIONAL APPLICATION NO. PCT/SE03/02033		
I.A. FILING DATE 12/19/2003	PRIORITY DATE	

44992  
ASTRAZENECA R&D BOSTON  
35 GATEHOUSE DRIVE  
WALTHAM, MA 02451-1215

CONFIRMATION NO. 8394  
371 FORMALITIES LETTER  
\*OC000000018213392\*

Date Mailed: 03/09/2006

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 06/16/2005
- Copy of the International Search Report filed on 06/16/2005
- Copy of IPE Report filed on 06/16/2005
- Information Disclosure Statements filed on 10/03/2005
- U.S. Basic National Fees filed on 06/16/2005
- Priority Documents filed on 06/16/2005
- Power of Attorney filed on 06/16/2005

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.138(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

MAK-23-2006 THU 02:59 PM astra zeneca r&d boston

FAX NO. 17818394121

P. 03 P.0

Page 2 of 2

DARRELL C COTTMAN

Telephone: (703) 308-9140 EXT 203

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/539,936	PCT/SP03/02033	100909-1P US

FORM PCT/DO/EO/805 (371 Formattiles Notice)

BEST AVAILABLE COPY